

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail

(Translation)

March 9, 2023

To Shareholders

Company Name Renascience Inc.
Name of Representative: Koji Naito, President & CEO
(Code: 4889 TSE Growth)
Inquiries to: Hiroyasu Ishimaru, Corporate Officer, in charge of
Administration and Corporate Planning

Notice of Revision of Full-Year Earnings Forecasts for the Fiscal Year Ending March 31, 2023

The Company resolved at a meeting on March 9, 2023, to revise its full-year earnings forecasts for the fiscal year ending March 31, 2023 (April 1, 2022, to March 31, 2023), as follows

Particulars

1. Revisions to the forecast of financial results for the current the fiscal year (April 1, 2022 - March 31, 2023)

	Operating revenue	Operating profit	Ordinary income	Net income for the year	Net income for the year (per share)
Previous forecast (A)	Millions of yen 90	Millions of yen △542	Millions of yen △542	Millions of yen △542	Yen Sen △42.70
Revised forecast (B)	100	△329	△329	△ 331	△26.06
Increase (Decrease) (B-A)	9	213	213	211	
Increase (Decrease) (%)	10.7	-	-	-	
(Reference) Results for the previous period (Fiscal year ended March 2022)	139	△210	△241	△254	△22.33

2. Reason for revision

We have reviewed our full-year results for the fiscal year ending March 31, 2022, and our new forecasts are as follows:

(Operating revenue)

The operating revenue is expected to increase by 9 million yen (10.7%) from the previous forecast.

The main reasons are, in addition to income from agreements with business companies, satisfactory and favorable development progress in the Japan Agency for Medical Research and Development (AMED) project, which resulted in the approval of an additional development budget.

(Operating income, ordinary income, and net income)

The operating income and ordinary income are expected to increase by 213 million yen and the net income by 211 million yen compared to the previous forecast.

These revisions are mainly due to a reduction of approximately 187 million yen in in-house R&D expenses as a result of utilizing public funds from AMED for the pipeline development of drugs for chronic myeloid leukemia (CML) and lung injury caused by novel coronavirus infection (COVID-19). Despite the reduction in in-house R&D expenses, the pipeline development (number and stage) progressed as planned as a result of efficient R&D activities that is one of our strengths.

*The above forecasts are based on evaluation and assumption made considering information available as of the date of publication of this document, and actual results may differ from such forecasts due to various factors in the future.

End